Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Pretomanid in Participants With Renal Impairment
NCT03896750Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pretomanid in Tuberculosis (TB) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity. Started Apr 2024; status: completed.
02
Drugs
pretomanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03896750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896750.